PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 16/00 | A2

(11) International Publication Number: WO 00/40615

(43) International Publication Date: 13 July 2000 (13.07.00)

(21) International Application Number: PCT/US00/00352

(22) International Filing Date: 7 January 2000 (07.01.00)

(30) Priority Data:
60/115,079 7 January 1999 (07.01.99) US

(71) Applicant: LEXIGEN PHARMACEUTICALS, CORP. [US/US]; 125 Hartwell Avenue, Lexington, MA 02173 (US).

(72) Inventors: LO, Kin-Ming; 6 Carol Lane, Lexington, MA 02420 (US). ZHANG, Jinyang; 8 Brattle Drive, Apt. 9, Arlington, MA 02474 (US). GILLIES, Stephen, D.; 159 Sunset Road, Carlisle, MA 01741 (US).

(74) Agent: GREENHALGH, Duncan, A.; Testa, Hurwitz & Thibeault, LLP, High Street Tower, 125 High Street, Boston, MA 02110 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

This Sheet Has Been Replaced



(54) Title: EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS

(57) Abstract

Disclosed are nucleotide sequences, for example, DNA or RNA sequences, which encode an immunoglobulin Fc–Leptin fusion protein. The nucleotide sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of immunoglobulin Fc–Leptin fusion proteins that can be produced by expression of such nucleotide sequences. Also disclosed are methods using such nucleotide sequences and fusion proteins for treating conditions which are alleviated by the administration of leptin.